Development of Herceptin

Breast Disease

Volumn 11, Issue , 2000, Pages 103-111

  Carter, P ^a   Fendly, B M ^a   Lewis, G D ^a   Sliwkowski, M X ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 4D5; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; ONCOGENE NEU; ONCOLOGY; PRIORITY JOURNAL; RAT;

EID: 0033853589     PISSN: 08886008     EISSN: None     Source Type: Journal    
DOI: 10.3233/BD-1999-11109     Document Type: Article

References (65)

1. Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas
2. The neu oncogene: An erb-B-related gene encoding a 185,000-Mr tumour antigen
3. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185
4. Neu receptor dimerization [letter]
5. A point mutation in the neu oncogene mimics ligand induction of receptor aggregation
6. Tyrosine phosphatase inhibition permits analysis of signal transduction complexes in p185HER2/neu-overexpressing human tumor cells
7. A single autophosphorylation site confers onogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway
8. Shc products are substrates of erbB-2 kinase
9. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
10. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor
11. Aaronson SA. Amplification of a novel v-erb-B-related gene in a human mammary carcinoma
12. Human breast cancer: Correlation of relapse and survival with amplification of the HER2/neu oncogene
13. The HER2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy
14. Aaronson SA. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells
15. Increased expression of the putative growth factor receptor p185(HER2) causes transformation and tumorigenesis of NIH 3T3 cells
16. Transformation mediated by the human HER2 gene independent of the epidermal growth factor receptor
17. HER2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells
18. Overexpression of ERBB-2 in human mammary epithelial cells signals inhibition of transcription of the E-cadherin gene
19. Expression of the neu protoncogene in the mammary epitheleum of transgenic mice induces metastatic disease
20. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product
21. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor
22. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies
23. Inhibitory effects of combinations of HER2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
24. Nonclinical studies addressing the mechanism of action of HERCEPTIN(®) (Trastuzumab)
25. The effect of HER2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells
26. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER2 receptor and DNA-reactive drugs
27. Antibody to HER2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells
28. Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer
29. Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic
30. Antibodies as carriers of cytotoxicity
31. The development of monoclonal antibodies for the therapy of cancer
32. The rise of monoclonal antibodies as therapeutics
33. Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma
34. Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy
35. Human immune response to monoclonal antibodies
36. Treatment with high dose mouse monoclonal (anti-GD3) antibody R24 in patients with metastatic melanoma
37. Replacing the complementarity-determining regions in a human antibody with those from a mouse
38. Reshaping human antibodies: Grafting an antilysozyme activity
39. Reshaping human antibodies for therapy
40. Human antibodies by design
41. A humanized antibody that binds to the interleukin 2 receptor
42. Sequences of proteins of immunological interest
43. Humanization of an anti-p185HER2 antibody for human cancer therapy
44. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies
45. Inhibition of human tumor growth by IgG2A monoclonal antibodies correlates with antibody density on tumor cells
46. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
47. Concurrent administration of anti-HER2 monoclonal antibody and first-line chemotherapy for HER2-overexpressing metastatic breast cancer: A phase iii, multinational, randomized, controlled trial
48. Metabolic properties of IgG subclasses in man
49. Humanization of an antibody directed against IgE
50. X-ray structures of fragments from binding and nonbinding versions of a humanized anti-CD18 antibody: Structural indications of the key role of VH residues 59 to 65
51. Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1
52. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders
53. High level Escherichia coli expression and production of a bivalent humanized antibody fragment
54. Improving in vivo folding and stability of a single-chain Fv antibody fragment by loop grafting
55. Phage display of a catalytic antibody to optimize affinity for transition-state analog binding
56. The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand
57. The biology of human epidermal growth factor receptor 2
58. Neuregulins and their receptors: A versatile signaling module in organogenesis and oncogenesis
59. Neuregulins and neuregulin receptors in neural development
60. Requirement for neuregulin receptor erb-B-2 in neural and cardiac development
61. Aberrant neural and cardiac development in mice lacking the ErbB-4 neuregulin receptor
62. Multiple essential functions of neuregulin in development
63. Signaling pathways for cardiac hypertrophy and failure
64. Stress pathways and heart failure